Inceptor Bio to establish cell and gene therapy company portfolio

By The Science Advisory Board staff writers

June 14, 2021 -- Inceptor Bio has raised $26 million in seed funding to create a portfolio of companies focused on developing next-generation cell and gene therapies targeting cancer based on its advanced manufacturing platform (AMP+).

Inceptor Bio was established in 2020 with the goal of developing a diversified portfolio of cell therapy platforms across multiple cell types, including chimeric antigen receptor (CAR) T-cells, CAR macrophage cells, and CAR natural killer (NK)/NK-T cells, with novel mechanisms that enhance immune cell performance within the tumor microenvironment.

These products are reliant on the company's AMP+ manufacturing facility, which is a fit-for-purpose, scalable site with viral vector and cell therapy capabilities.

The seed round was led by the Kineticos Disruptor Fund.

Copyright © 2021

HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter